New Zealand launches first stage of HPV vaccine
This article was originally published in Scrip
More than 50,000 New Zealand women can now access the first stage of the country's human papilloma virus immunisation programme, which began on September 1st. Women aged 17-18 years old can receive the first of three of Merck & Co's Gardasil vaccinations via their GP or nurse. Younger women aged 12-18 will be offered the vaccine next year, predominantly through schools. The government will spend around NZ$177 million ($117 million) on the programme over the next five years, accruing an ongoing cost of around NZ$16 million per year.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).